Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Pharvaris BV

Healthcare US PHVS

32.8USD
-0.61(1.83%)

Last update at 2026-06-18T20:00:00Z

Day Range

32.3434.41
LowHigh

52 Week Range

8.2033.00
LowHigh

Fundamentals

  • Previous Close 33.41
  • Market Cap1086.02M
  • Volume182167
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-104.13469M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.69

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -97.78003M -75.65347M -42.66066M -26.06895M -8.02716M
Minority interest - - - - -
Net income -98.80734M -76.33256M -42.73078M -25.98570M -8.04404M
Selling general administrative 31.14M 29.34M 18.35M 5.50M 2.33M
Selling and marketing expenses 30.41M - - - -
Gross profit -0.25227M -0.15019M -0.08046M - -0.00055M
Reconciled depreciation 0.24M 0.15M 0.08M 0.00740M 0.00055M
Ebit -94.92709M -86.73776M -65.89910M -25.01280M -7.99340M
Ebitda -94.67482M -86.58482M -65.82173M -25.00540M -7.99285M
Depreciation and amortization 0.25M 0.15M 0.08M 0.00740M 0.00055M
Non operating income net other - - - - -
Operating income -94.92709M -86.73776M -65.89910M -25.01280M -7.99340M
Other operating expenses 94.93M 86.71M 54.14M 25.01M 8.01M
Interest expense 0.02M 0.02M 0.28M 0.09M 0.00438M
Tax provision 0.60M 0.68M 0.07M -0.08325M 0.00000M
Interest income - - - - -
Net interest income 0.21M -0.03925M -0.28251M -0.09868M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.03M 0.68M 0.07M -0.08325M 0.02M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 94.67M 86.71M 54.14M 25.01M 8.01M
Cost of revenue 0.25M 0.15M 0.08M - 0.00055M
Total other income expense net -2.85294M 11.08M 23.24M -1.05615M -0.03376M
Discontinued operations - - - - -
Net income from continuing ops -107.32407M -76.33256M -42.73078M -25.98570M -8.02716M
Net income applicable to common shares - -76.33256M -42.73078M -25.98570M -8.02716M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 399.02M 167.73M 212.09M 101.10M 20.60M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 5.59M 0.58M 0.00570M 1.21M 0.05M
Total liab 14.66M 18.47M 7.14M 5.31M 1.92M
Total stockholder equity 384.37M 149.26M 204.95M 95.79M 18.67M
Deferred long term liab - - - - -
Other current liab 11.08M 12.06M 4.76M 4.47M 1.41M
Common stock 6.28M 4.06M 3.98M 0.24M 0.13M
Capital stock 6.27M 4.06M 3.98M 0.24M 0.13M
Retained earnings -266.13787M -164.18889M -87.56840M -44.45995M -18.47425M
Other liab - - - - -
Good will - - - - -
Other assets - 0.26M -0.00000M - -
Cash 391.55M 161.84M 209.35M 98.63M 20.33M
Cash and equivalents - - - - -
Total current liabilities 14.61M 18.22M 6.99M 5.31M 1.92M
Current deferred revenue 0.43M - - - -
Net debt -391.31509M -161.40061M -209.10295M -98.62887M -20.32637M
Short term debt 0.20M 0.19M 0.10M - -
Short long term debt - - - - -
Short long term debt total 0.24M 0.44M 0.25M - -
Other stockholder equity 616.32M 289.18M 278.74M 138.03M 36.62M
Property plant equipment - 0.63M 0.35M 0.05M 0.01M
Total current assets 398.18M 166.85M 211.57M 100.95M 20.58M
Long term investments - - - - -
Net tangible assets - 149.26M 204.95M 95.60M 18.59M
Short term investments - - - - -
Net receivables 1.04M 0.38M 0.70M 0.57M 0.21M
Long term debt - - - - -
Inventory 0.00000M 4.04M 1.51M 0.54M -
Accounts payable 2.91M 5.98M 2.13M 0.85M 0.51M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 27.90M 20.21M 9.80M 1.98M 0.39M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00000M - - - -
Deferred long term asset charges - - - - -
Non current assets total 0.84M 0.89M 0.52M 0.15M 0.01M
Capital lease obligations 0.24M 0.44M 0.25M - -
Long term debt total - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -0.08524M -0.12430M -0.13003M -0.04298M -0.01348M
Change to liabilities - 3.91M 1.66M 0.33M 0.27M
Total cashflows from investing activities - -0.12430M -0.13003M -0.04298M -0.01348M
Net borrowings - -0.11953M -0.11953M -0.11953M -0.11953M
Total cash from financing activities 318.72M 8.65M 143.67M 101.20M 21.63M
Change to operating activities - 4.15M 0.04M 1.60M 1.15M
Net income -98.80734M -75.65347M -42.66066M -26.06895M -8.02716M
Change in cash 230.17M -47.51570M 110.72M 78.30M 14.94M
Begin period cash flow 161.38M 209.35M 98.63M 20.33M 5.39M
End period cash flow 391.55M 161.84M 209.35M 98.63M 20.33M
Total cash from operating activities -91.14178M -67.16263M -44.59968M -21.49959M -6.67701M
Issuance of capital stock 64.20M 9.61M 156.83M 102.51M 22.47M
Depreciation 0.25M 0.15M 0.08M 0.00740M 0.00055M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -0.00000M 0.15M -0.06284M - 0.00358M
Change to account receivables -0.04021M 0.31M -0.13571M -0.00036M -0.20873M
Sale purchase of stock - - - - -
Other cashflows from financing activities -17.29781M -0.83997M -13.15436M -1.31408M -0.83618M
Change to netincome - 0.64M -3.52158M 2.91M 0.11M
Capital expenditures 0.09M 0.12M 0.13M 0.04M 0.01M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -5.74248M 8.38M 1.58M 1.57M 1.24M
Stock based compensation 10.66M 11.35M 8.20M 1.59M 0.12M
Other non cash items 17.79M -11.38820M 0.27M 0.10M -0.00369M
Free cash flow -91.22992M -67.28693M -44.72971M -21.54257M -6.69049M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
PHVS
Pharvaris BV		 -0.61 1.83% 32.80 - - - 2.86 -6.9987
NVO
Novo Nordisk A/S		 -0.33 0.76% 43.19 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 43.40 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -7.36 1.60% 451.63 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.01 0.33% 609.94 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Pharvaris BV

Emmy Noetherweg 2, Leiden, Netherlands, 2333 CH

Key Executives

Name Title Year Born
Mr. Berndt Axel Edvard Modig CPA, M.B.A., MBA Co-Founder, CEO & Exec. Director 1959
Ms. Anna Nijdam M.Sc., R.A. Head of Fin. & Principal Accounting Officer 1981
Dr. Jochen Knolle Ph.D. Chief Scientific Officer & COO 1950
Ms. Joan Schmidt J.D. Chief Legal Officer 1964
Maryann Cimino Director of Corp. Relations NA
Ms. Annick Deschoolmeester Chief HR Officer NA
Dr. Peng Lu M.D., Ph.D. Chief Medical Officer 1978
Dr. Anne Lesage Ph.D. Chief Early Devel. Officer 1961
Dr. Morgan Conn Ph.D. Chief Bus. Officer 1969
Mr. Wim Souverijns Ph.D. Chief Community Engagement & Commercial Officer 1971

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions